An Open-Label, Multicentre Study of Levocetirizine for the Treatment of Allergic Rhinitis and Urticaria in Taiwanese Patients

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/16389

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/16389

题名:	An Open-Label, Multicentre Study of Levocetirizine for the Treatment of Allergic Rhinitis and Urticaria in Taiwanese Patients
作者:	;Fang, Sheen-Yie;Perng, Diahn-Warng;Lee, J.Yu-Yun;Lin, Ding-Yu;黃志揚;HUANG, CHIH-YANG
贡献者:	生物科技學系
关键词:	"allergic rhinitis, urticaria, levocetirizine, patient perception, persistent allergic rhinitis, intermittent allergic rhinitis"
日期:	2010-01
上传时间:	2012-11-23 09:12:26 (UTC+0)
摘要:	"Levocetirizine has been shown in observational studies in the west as an effective and satisfactory therapy for patients with allergic respiratory and skin disease. An open-label, multicentre observational study was conducted to investigate the patients’ perception of levocetirizine in the treatment of allergic rhinitis (AR) and urticaria in Taiwanese patients. Three hundred and thirty-three patients (236 AR and 97 urticaria patients) attending out-patient clinics of medical centres across Taiwan were included in the study. Patients were treated with levocetirizine 5 mg once daily (AR patients for 2-4 weeks and urticaria patients for 2-6 weeks) and at the end of treatment, they evaluated for symptoms of disease, perception of change in symptoms, global efficacy and tolerability, global preference over previous antiallergic treatment, change in quality of sleep/daily activities, and safety and adverse events (AEs). Levocetirizine markedly improved the symptoms of AR and urticaria; with 70-75% of AR patients and 60-80% of urticaria patients reporting complete or marked improvements in individual symptoms. Asthma symptoms were completely or markedly improved in 44% of patients with AR and concomitant asthma. A majority of the patients was satisfied with levocetirizine therapy and 50-70% indicated preference for levocetirizine over previous therapy. Overall, 50-74% of all patients perceived improvements in quality of sleep/daily activities and 50-65% of the patients rated the onset of action for levocetirizine as very rapid or rapid. Somnolence was the most common AE, reported by 7.4% of AR and 7.0% of urticaria patients. The results of this study indicated that levocetirizine is an effective and satisfactory therapy for the management of allergic respiratory and skin disease in Taiwanese subjects."
關聯:	CHINESE JOURNAL OF PHYSIOLOGY
显示于类别:	[生物科技學系] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	433	检视/开启

在ASIAIR中所有的数据项都受到原著作权保护.

数据加载中.....